Saturday, June 13, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 237 of 1,261
  1. US 11453683

    KRas G12D inhibitors

    Mirati Therapeutics, Inc. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  2. US 11453714

    Human antibodies to influenza hemagglutinin

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  3. US 11452782

    Liver-specific constructs factor VIII expression cassettes and methods of use thereof

    Sangamo Therapeutics, Inc. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  4. US 11453700

    Peptide having activities of skin whitening and uses thereof

    CAREGEN CO., LTD. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  5. US 11452724

    Methods for treating amyotrophic lateral sclerosis

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  6. US 11452717

    Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  7. US 11453891

    Directed editing of cellular RNA via nuclear delivery of CRISPR/CAS9

    The Regents of the University of California · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  8. US 11453861

    Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

    Precision BioSciences, Inc. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  9. US 11452780

    Mtorc1 inhibitors

    The Regents of the University of California · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  10. US 11452721

    Formulations of pimavanserin

    ACADIA Pharmaceuticals Inc. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  11. US 11452725

    Chiral diaryl macrocycles and uses thereof

    TURNING POINT THERAPEUTICS, INC. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  12. US 11453655

    Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Vertex Pharmaceuticals Incorporated · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  13. US 11452714

    Antibacterial agents including histidine kinase inhibitors

    Regents of the University of Minnesota · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  14. US 11452775

    Detection of arginine methylation of EGFR for prediction of resistance to therapy

    The Board of Regents of the University of Texas System · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  15. US 11452674

    Non-solvent dental adhesive composition

    KURARAY NORITAKE DENTAL INC. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  16. US 11453785

    Method for producing surface-treated colored inorganic particles

    KURARAY NORITAKE DENTAL INC. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  17. US 11452691

    Compositions of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  18. US 11453710

    Activatable interleukin 12 polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  19. US 11453640

    Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy

    Northwestern University · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  20. US 11453725

    Methods for DNA-dependent targeting of a cell permeant antibody

    United States Government as represented by the Department of Veterans Affairs · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  21. US 11452723

    Combination dosage form of a mu opioid receptor antagonist and an opioid agent

    Theravance Biopharma R&D IP, LLC · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  22. US 11452709

    Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  23. US 11453661

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  24. US 11453870

    Ligase fusion proteins and application thereof

    GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.